Cartesian Therapeutics IncNASDAQ:RNAC
- LAST PRICE21.0300
- TODAY'S CHANGE (%)0.1300 (0.6220%)
- Bid / Lots19.2500/ 2
- Ask / Lots21.7900/ 2
- Open / Previous Close20.9800 / 20.9000
- Day Range
- 52 Week Range
- Volume123,840
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | RNAC |
|---|---|---|
| 09:32 ET | 941 | 20.98 |
| 09:43 ET | 366 | 20.71 |
| 09:50 ET | 100 | 20.74 |
| 09:59 ET | 100 | 20.72 |
| 10:08 ET | 100 | 20.74 |
| 10:32 ET | 821 | 20.99 |
| 10:35 ET | 100 | 20.87 |
| 10:39 ET | 100 | 20.845 |
| 10:48 ET | 100 | 20.85 |
| 10:53 ET | 100 | 20.73 |
| 11:06 ET | 200 | 20.77 |
| 11:08 ET | 100 | 20.74 |
| 11:09 ET | 907 | 20.84 |
| 11:18 ET | 450 | 20.9 |
| 11:24 ET | 1600 | 20.83 |
| 11:27 ET | 100 | 20.85 |
| 11:29 ET | 100 | 20.84 |
| 11:38 ET | 200 | 20.88 |
| 11:54 ET | 830 | 20.93 |
| 11:56 ET | 800 | 20.93 |
| 11:58 ET | 100 | 20.995 |
| 12:02 ET | 200 | 20.99 |
| 12:07 ET | 1127 | 21.09 |
| 12:09 ET | 100 | 21.19 |
| 12:12 ET | 400 | 21.2 |
| 12:18 ET | 100 | 21.39 |
| 12:57 ET | 480 | 21.2 |
| 01:08 ET | 100 | 21.42 |
| 01:10 ET | 700 | 21.42 |
| 01:12 ET | 200 | 21.5 |
| 01:17 ET | 100 | 21.54 |
| 01:30 ET | 23500 | 21.415 |
| 01:33 ET | 100 | 21.495 |
| 01:35 ET | 706 | 21.7399 |
| 01:42 ET | 200 | 21.71 |
| 01:44 ET | 200 | 21.73 |
| 01:46 ET | 700 | 21.72 |
| 01:48 ET | 300 | 21.72 |
| 01:51 ET | 100 | 21.6 |
| 01:53 ET | 15000 | 21.55 |
| 01:55 ET | 100 | 21.68 |
| 02:06 ET | 105 | 21.57 |
| 02:09 ET | 100 | 21.47 |
| 02:33 ET | 300 | 21.415 |
| 02:40 ET | 400 | 21.33 |
| 02:42 ET | 100 | 21.395 |
| 02:45 ET | 300 | 21.22 |
| 03:05 ET | 200 | 21.24 |
| 03:07 ET | 200 | 21.35 |
| 03:12 ET | 500 | 21.2 |
| 03:16 ET | 900 | 21.22 |
| 03:21 ET | 100 | 21.04 |
| 03:25 ET | 108 | 21.14 |
| 03:32 ET | 1840 | 21.095 |
| 03:34 ET | 100 | 20.97 |
| 03:45 ET | 100 | 21.06 |
| 03:48 ET | 10250 | 20.98 |
| 03:50 ET | 534 | 21 |
| 03:52 ET | 279 | 21.07 |
| 03:54 ET | 100 | 21.075 |
| 03:56 ET | 30300 | 21 |
| 03:59 ET | 7278 | 21.03 |
Apr 23, 2024
DJ Cartesian Therapeutics Is Maintained at Buy by HC Wainwright & Co., from 12:32PM ET on Tuesday Apr 23, 2024 by Dow Jones
12:32PM ET on Tuesday Apr 23, 2024 by Dow JonesDJ Cartesian Therapeutics Initiated at Outperform by Leerink Partners, from 9:54AM ET on Tuesday Apr 23, 2024 by Dow Jones
9:54AM ET on Tuesday Apr 23, 2024 by Dow Jones
Apr 22, 2024
Cartesian Therapeutics to Present at the ASGCT 27th Annual Meeting, from 4:30PM ET on Monday Apr 22, 2024 by Dow Jones
4:30PM ET on Monday Apr 22, 2024 by Dow Jones
Apr 10, 2024
DJ Cartesian Therapeutics Price Target Maintained With a $42.00/Share by Needham, from 7:27AM ET on Wednesday Apr 10, 2024 by Dow Jones
7:27AM ET on Wednesday Apr 10, 2024 by Dow Jones
Apr 9, 2024
DJ Cartesian Therapeutics Initiated at Buy by Needham, from 12:27PM ET on Tuesday Apr 09, 2024 by Dow Jones
12:27PM ET on Tuesday Apr 09, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Cartesian Therapeutics Inc | 373.9M | -0.5x | --- |
TScan Therapeutics Inc | 368.2M | -2.9x | --- |
C4 Therapeutics Inc | 423.3M | -2.3x | --- |
Mersana Therapeutics Inc | 356.6M | -2.0x | --- |
Caribou Biosciences Inc | 335.1M | -2.6x | --- |
Iteos Therapeutics Inc | 387.1M | -3.4x | --- |
Company Information
Cartesian Therapeutics, Inc. is a clinical-stage company. The Company is engaged in developing messenger ribonucleic acids (mRNA) cell therapies for the treatment of autoimmune diseases. It is leveraging its proprietary technology and manufacturing platform, RNA Armory, to develop mRNA cell therapies for autoimmune diseases. Its lead asset e, Descartes-08, is an autologous mRNA chimeric antigen receptor T-cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), that the Company is developing for the treatment of autoimmune diseases. Descartes-08 is in Phase II clinical development. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.
Contact Information
- Headquarters
- 65 Grove StreetWATERTOWN, MA, United States 02472
- Phone
- 617-923-1400
- Fax
- 617-924-3454
Executives
- Independent Chairman of the Board
- Carrie Cox
- President, Chief Executive Officer, Director
- Carsten Brunn
- Chief Financial Officer
- Blaine Davis
- Chief Operating Officer
- Metin Kurtoglu
- Chief Scientific Officer
- Chris Jewell
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $373.9M |
|---|---|
Revenue (TTM) | $26.0M |
Shares Outstanding | 17.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.55 |
EPS | $-41.77 |
Book Value | $-25.87 |
P/E Ratio | -0.5x |
Price/Sales (TTM) | 14.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -332.32% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
